Opioid-Sparing Multimodal Analgesia in Enhanced Recovery After Surgery Protocols: A comprehensive Review

Postoperative pain management remains a critical component of surgical care, yet traditional opioid-centric approaches have contributed to widespread adverse effects, including the ongoing opioid epidemic. Enhanced Recovery After Surgery (ERAS) protocols represent a paradigm shift toward multimodal, patient-centered perioperative care designed to minimize surgical stress, accelerate recovery, and reduce complications. Central to these protocols is opioid-sparing multimodal analgesia (MMA), which integrates pharmacological agents, regional anesthesia techniques, and non-pharmacological interventions to target diverse pain pathways while minimizing opioid reliance. This narrative review synthesizes current evidence on opioid-sparing strategies within ERAS frameworks, drawing from meta-analyses, randomized controlled trials (RCTs), and guidelines from bodies like the ERAS Society and American Society of Anesthesiologists (ASA). Key pharmacological agents discussed include acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), gabapentinoids, alpha-2 agonists (e.g., dexmedetomidine), N-methyl-D-aspartate (NMDA) antagonists (e.g., ketamine), and lidocaine infusions. Regional techniques such as epidural analgesia, transversus abdominis plane (TAP) blocks, and peripheral nerve blocks are highlighted for their synergistic effects. Evidence across surgical specialties—abdominal, thoracic, orthopedic, urologic, and head and neck—demonstrates reductions in postoperative opioid consumption, pain scores, postoperative nausea and vomiting (PONV), hospital length of stay (LOS), and complications, though benefits vary by procedure and patient factors. Challenges include hemodynamic risks from certain agents, implementation barriers in ambulatory settings, and the need for personalized approaches in high-risk populations (e.g., chronic opioid users or those with comorbidities). Future directions emphasize artificial intelligence (AI)-driven risk prediction, objective pain assessment tools, and large-scale RCTs to refine protocols. By prioritizing opioid-sparing MMA, ERAS pathways not only enhance immediate recovery but also mitigate long-term risks like chronicpostsurgical pain (CPSP) and opioid dependency, aligning with broader public health goals. This review underscores the evolution from opioid-dominant to balanced, evidence-based analgesia, offering implications for clinical practice, education, and policy